BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, December 25, 2025
Breaking News: BioWorld 2025 Year in ReviewBreaking News: BioWorld MedTech 2025 Year in ReviewBreaking News: Trump administration impacts continue to roil the life sciences sector
Home » Topics » BioWorld, Regulatory

BioWorld, Regulatory
BioWorld, Regulatory RSS Feed RSS

Regulatory actions for June 26, 2020

June 26, 2020
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Aadi, Abbvie, Acceleron, Allergan, Ascendis, Axsome, BMS, Celltex, Chiasma, Citius, Daiichi Sankyo, Eisai, ERC Belgium, Gilead, Hansa, Molecular Partners, Novartis, Pfenex, Philogen, Samsung.
Read More
FDA icons
AACR Virtual Meeting II

FDA doles out advice to cancer companies

June 25, 2020
By Brian Orelli
At a session of the American Association for Cancer Research Virtual Annual Meeting II, multiple FDA regulators gave presentations on various topics to help drug companies understand the ever-evolving oncology regulation.
Read More

Regulatory front for June 25, 2020

June 25, 2020
The latest global regulatory news, changes and updates affecting biopharma, including: Alcon, Novartis, Regeneron, Roche.
Read More

Regulatory actions for June 25, 2020

June 25, 2020
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: EMD Serono, Genprex, Medivir, Merck, Sinovac, Tizona, Viracta.
Read More

Regulatory actions for June 24, 2020

June 24, 2020
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Fulcrum, GBT, Hemoshear, Imara, Innate, Mayne, Medigene, Neurorx, Novartis, Relief, Philogen.
Read More

Regulatory front for June 24, 2020

June 24, 2020
The latest global regulatory news, changes and updates affecting biopharma, including: Gilead, Kymab, Regeneron.
Read More

Regulatory actions for June 23, 2020

June 23, 2020
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Immunovative, Mirror Biologics, Karuna, Karyopharm, Marker, Myovant, Novaremed, Pharmacyclics, Polynoma, Reneo, Renibus, Santhera.
Read More
FDA approved metal stamp

Karyopharm’s Xpovio receives a second FDA approval

June 22, 2020
By Lee Landenberger
Xpovio (selinexor), an oral selective inhibitor of nuclear transport from Karyopharm Therapeutics Inc., of Newton, Mass., received FDA approval today for treating adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), including DLBCL arising from follicular lymphoma, after at least two lines of systemic therapy. Xpovio will be available immediately in the U.S., the company said, and, due to COVID-19 restrictions, the launch will be a virtual one.
Read More

India’s Glenmark Pharmaceuticals gets green light to launch $1 COVID-19 treatment tablets

June 22, 2020
By David Ho
HONG KONG - Mumbai-based Glenmark Pharmaceuticals Ltd. has been granted manufacturing and marketing approval for the launch of its antiviral drug, favipiravir, for the treatment of mild to moderate COVID-19, a move it deems a “landmark development for COVID-19 patients in India.”
Read More

Nabriva's Contepo NDA derailed by COVID-19

June 22, 2020
By Michael Fitzhugh
A second attempt by Nabriva Therapeutics plc to win U.S. approval for the antibiotic Contepo (fosfomycin) has been undone by COVID-19. Manufacturing issues stymied the original NDA. This time, restrictions of FDA staff travel to Europe sunk the venture, leading to a new complete response letter (CRL) for the candidate as a potential treatment of complicated urinary tract infections (cUTI), including acute pyelonephritis.
Read More
Previous 1 2 … 387 388 389 390 391 392 393 394 395 … 431 432 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 24, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 24, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Acute myeloid leukemia illustration

    Apollo’s APL-4098 shows potent antileukemic effects

    BioWorld Science
    Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
  • Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

    HIV research is close to a cure but far from ending the pandemic

    BioWorld
    Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing